课题基金 / 基金详情

Journey to the Center of the Cell: Reprogramming intracellular transport to the nucleus enhances HER2+ tumor killing for trastuzumab conjugated to payloads active in the nucleus

Journey to the Center of the Cell: Reprogramming intracellular transport to the nucleus enhances HER2+ tumor killing for trastuzumab conjugated to payloads active in the nucleus
细胞中心之旅：重编程细胞内至细胞核的运输可增强与细胞核中活性有效负载缀合的曲妥珠单抗的 HER2 肿瘤杀伤作用
批准号：
445112
负责人：
Leyton Jeffrey V
金额：
$42.35万
依托单位：
Universit de Sherbrooke
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-04-01 至 2026-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=445112&lang=en
关键词：
Antibody-Based Therapeutics Nls-Based Targeted Therapeutics Nuclear Localization Signals (Nls)

项目摘要

项目成果

Leyton Jeffrey V的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The nucleus is the organelle controlling the expression of gene products, with functions necessary for cellular survival. Nuclear targeting is a potential tool for improving the efficacy of chemotherapy, vaccines, and gene therapy. Research focused on und
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The great escape: Improving the activity of chemotherapeutics delivered by antibody-drug conjugates with integrated endosome escape and nuclear-directional trafficking control capabilies
  • 批准号：
    358262
  • 项目类别：
    Operating Grants
  • 资助金额：
    $41.16万
  • 财政年份：
    2016
  • 负责人：
    Leyton Jeffrey V
  • 依托单位：
    Universit de Sherbrooke